Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:753480.
doi: 10.1155/2015/753480. Epub 2015 Mar 26.

Estimation of an optimal chemotherapy utilisation rate for upper gastrointestinal cancers: setting an evidence-based benchmark for the best-quality cancer care

Weng Ng  1 , Susannah Jacob  1 , Geoff Delaney  1 , Viet Do  1 , Michael Barton  1
Affiliations

Estimation of an optimal chemotherapy utilisation rate for upper gastrointestinal cancers: setting an evidence-based benchmark for the best-quality cancer care

Weng Ng et al. Gastroenterol Res Pract. 2015.

Abstract

Aims. The proportion of patients with upper gastrointestinal cancers that received chemotherapy varies widely in Australia and internationally, indicating a need for a benchmark rate of chemotherapy utilisation. We developed evidence-based models for upper gastrointestinal cancers to estimate the optimal chemotherapy utilisation rates that can serve as useful benchmarks for measuring and improving the quality of care. Materials and Methods. Optimal chemotherapy utilisation models for cancers of the oesophagus, stomach, pancreas, gallbladder, and primary liver were constructed using indications for chemotherapy identified from evidence-based guidelines. Results. Based on the best available evidence, the optimal proportion of upper gastrointestinal cancers that should receive chemotherapy at least once during the course of the patients' illness was estimated to be 79% for oesophageal cancer, 83% for gastric cancer, 35% for pancreatic cancer, 80% for gallbladder cancer, and 27% for primary liver cancer. Conclusions. The reported chemotherapy utilisation rates for upper gastrointestinal cancers (with the exception of primary liver cancer) appear to be substantially lower than the estimated optimal rates suggesting that chemotherapy may be underutilised. Further studies to elucidate the reasons for the potential underutilisation of chemotherapy in upper gastrointestinal tumours are required to bridge the gap between the ideal and actual practice identified.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Optimal chemotherapy utilisation tree for oesophageal and gastric cancers.
Figure 2
Figure 2
Optimal chemotherapy utilisation tree for pancreatic, liver, and gallbladder cancers.
See this image and copyright information in PMC

References

    1. Hewitt M., Simone J. Ensuring Quality Cancer Care. Washington, DC, USA: National Academy Press; 1999. - PubMed
    1. Verdecchia A., Francisci S., Brenner H., et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. The Lancet Oncology. 2007;8(9):784–796. doi: 10.1016/s1470-2045(07)70246-2. - DOI - PubMed
    1. Australian Institute of Health and Welfare (AIHW) Cancer in Australia 2003. Canberra, Australia: Australian Institute of Health and Welfare; 2007. (Cancer Series No. 37).
    1. Delaney G., Barton M., Jacob S. Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence. Cancer. 2004;101(4):657–670. - PubMed
    1. Cance W. G., Stewart A. K., Menck H. R. The National Cancer Data Base report on treatment patterns for Hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996. Cancer. 2000;88(4):912–920. doi: 10.1002/(sici)1097-0142(20000215)88:4x0003C;912::aid-cncr23x003E;3.0.co;2-t. - DOI - PubMed

LinkOut - more resources